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Recombinant versus natural human 111In-b2-microglobulin for b2-Microglobulin (b2m)-associated amyloidosis (Ab2m;
scintigraphic detection of Ab2m amyloid in dialysis patients. with Ab2m referring to the circulating precursor mole-
Background. We previously introduced scintigraphy with cule b2m [1]) represents a major cause or morbidity and131I-labeled b2-microglobulin (b2m), purified from uremic hem-
potential mortality in the growing population of patientsofiltrate, that is, “natural” b2m, to specifically detect b2m-associ-
with long-standing end-stage renal disease [2–4]. Theated amyloidosis (Ab2m) in hemodialysis (HD) patients.
Methods. To improve the safety and resolution of the scan, clinical and radiological features of Ab2m are mainly
we covalently bound the chelator diethylenetriaminepentaace- related to periarticular and synovial amyloid deposition,
tic acid to natural b2m to allow radiolabeling with 111In. In a while visceral manifestations are rare. Conventional di-second step, we generated and evaluated the usage of recombi-
agnostic techniques for Ab2m suffer from either invasive-nant human b2m (rhb2m) for scintigraphy.
Results. Using natural 111In-labeled b2m, eight patients on ness (biopsy of selected tissues) or relative nonspecificity
HD for 0 to 17 years, without evidence of Ab2m, were scanned. [clinical symptomatology; joint ultrasonography; demon-
Whole-body scintigraphy at 48 to 72 hours postinjection re- stration of “cystic” bone lesions by x-ray study, computedvealed no significant tracer accumulation over joint regions.
tomography (CT) scan, or magnetic resonance tomogra-In contrast, nine patients on HD for 10 to 21 years with clinical,
phy (MRT)] [5]. A novel, noninvasive approach to diag-radiological, or histologic (N 5 4) evidence of Ab2m showed
selective tracer uptake over various joint regions. Tracer accu- nose Ab2m amyloidosis was based on the injection of
mulation in visceral organs, which could not be related to tracer the radiolabeled amyloid precursor protein b2m [6]. Thiselimination or metabolism, was not detected. Compared with method allowed the specific and sensitive detection ofthe previous 131I b2m scan, scintigraphy with 111In-labeled b2m
Ab2m amyloid deposits in end-stage renal disease pa-offered highly improved image contrast, increased sensitivity,
and a 50 to 70% reduction of the radiation exposure. Scanning tients [6, 7]. In the original method, we had labeled the
with 111In-labeled recombinant human b2m was performed in purified b2m with 131iodine (131I) using the chloramine-T
six patients: No significant tracer accumulation was observed method [8]. This approach suffered from the disadvan-
over joint regions in two patients on short-term HD without
tage that chloramine-T induces some denaturing and/orevidence of Ab2m; in contrast, local tracer accumulations simi-
cross-linking of the protein. More importantly, the usagelar to those observed with natural b2m could be demonstrated
in four long-term (10 to 27 years) HD patients with clinical, of 131I appeared suboptimal given the long half-life (8 days)
radiological, and histologic (N 5 1) evidence of Ab2m. of 131I, the heterogeneous radiation spectrum (b in addi-
Conclusion. Scintigraphy for Ab2m with 111In-labeled rhb2m tion to g radiation), and the resulting radiation exposureprovides a homogenous and safe recombinant protein source
to the patient. We therefore employed a modified labelingand leads to enhanced sensitivity and lower radiation exposure.
method in which b2m is coupled to 111indium (111In, half-
life 2.8 days, exclusive g radiation) following the prior
conjugation of the chelator diethylenetriaminepentaace-
tic acid (DTPA) to b2m. In a subsequent step, we have
attempted to abandon the usage of human b2m purified
from uremic plasma hemofiltrate [6, 7]. To obtain a moreKey words: hemodialysis, arthropathy, uremia, radiation exposure,
end-stage renal disease, noninvasive detection technique. standardized preparation of the protein, as well as to
improve the safety of the scan, we have therefore gener-Received for publication November 29, 1999
ated recombinant b2m. Here we report our first experi-and in revised form February 14, 2000
Accepted for publication March 14, 2000 ence with switching from iodine to indium labeling as
well as switching from natural to recombinant b2m.Ó 2000 by the International Society of Nephrology
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METHODS was allowed to stand for 15 minutes at room temperature.
Gel chromatography followed by sterile filtration yieldedb2-Microglobulin
up to 250 MBq of 111In-DTPA-b2m containing 3 to 12%Isolation of b2m from uremic hemofiltrate. b2-Micro- unbound indium.
globulin was isolated as described previously [6, 7] from Sterility and the lack of pyrogenicity of the material were
plasma ultrafiltrate of a single chronic hemodialysis (HD) assured by culture, limulus amebocyte lysate (LAL) test,
patient without residual renal function who had no other and a rabbit pyrogen assay.
intercurrent illnesses and who had been treated at our
institution for the last 12 years. The patient had had Scintigraphy with indium-labeled b2m
consistently normal liver enzymes as well as negative Informed consent was obtained from all patients prior
tests for hepatitis B, hepatitis C, and HIV-I and HIV-II to injection. The protocol was approved by the ethics
viruses. Prior to usage of the purified b2m for scintigra- committee of the Hannover Medical School.
phy, a six-month quarantine period was included, after Between 0.6 and 1.0 MBq/kg body weight (that is, 37
which the tests for hepatitis and HIV viruses were re- to 78 MBq) of sterile, pyrogen-free 111In-DTPA-(rh)b2mpeated in the patient. Purity and integrity of the purified was injected intravenously on day 0; anterior and poste-
protein were confirmed by sodium dodecyl sulfate-poly- rior whole-body scintigraphy was performed after 48 to
acrylamide gel electrophoresis (SDS-PAGE), Western 72 hours. Additional planar images of selected regions
blot analysis, and high-performance liquid chromatogra- were taken to improve the image quality (Siemens DIA-
phy (HPLC). The protein was stored in lyophilized form CAM Gamma-Camera). Usually, one HD treatment was
until used for labeling. performed between injection and scintigraphy with a
Generation of recombinant human b2m. Recombinant b2m-impermeable, low-flux membrane. In the last three
human b2m (rhb2m) was produced in transformed Esche- cases of scintigraphy with rhb2m, where the scan was
richia coli cells with the expression vector [pASK40(dL- performed after 72 hours, a second dialysis treatment
hub2m(His)5] coding for human b2m with five histidine immediately prior to the imaging was performed using
residues attached at the carboxy terminus [9]. Recombi- a b2m-permeable, high-flux filter in order to maximize
nant bacteria were propagated in ampicillin-supplemented removal of circulating tracer and thus reduce background
medium. Fermentation was done in the absence of antibi- activity. In two patients, serial scintigraphies were ob-
otics in a 100 L fermenter. After harvesting and disrup- tained 1, 24, 48, and 72 hours after the injection. Dosime-
tion of the cells, a series of purification steps, including try based on repeated scintigraphy and plasma samples
anion-exchange chromatography, metal-chelating Seph- was performed in one completely anuric chronic HD
arose column, and size-exclusion chromatography, was patient to obtain an estimate of the effective whole-body
performed. The obtained protein pool was concentrated radiation dose. Tracer accumulation was expressed in a
and diafiltrated, and finally sterile filtrated (0.22 mm fil- semiquantitative manner (0 5 absent, 1 5 faint, 2 5
ter) and stored at 2808C. Quality control studies of the moderate, and 3 5 strong); soft tissue activity in the
rhb2m solution included determination of protein con- thigh was used to define background activity, and uptake
centration (1.1 mg/mL), immunoreactivity with anti-b2m in the liver served as the reference area for maximum
antibody (Mancini, 1.2 mg/mL), SDS-PAGE (100% pu- accumulation. All scan images were evaluated by at least
rity), Western blot analysis (immunoreactivity with anti- two of the investigators who were not aware of the clini-
b2m antibody, single band), size-exclusion HPLC (100% cal status of the patients. Concordance between readers
purity), tests for endotoxin (not detectable) and sterility, was very high; the interreader difference was always
isoelectric focusing (main band at pH 6.9, small addi- ,10% of the maximal score; the total score for all pa-
tional band at pH 6.6), and N-terminal sequence analysis tients/all regions differed by one point between readers.
(I-Q-R-T-P-K-I-Q-V-Y-S-R-H-P-A, that is, identical to
Patientsthe known human b2m sequence).
A total of 23 chronic HD patients were studied: 16
Radioactive labeling males and 7 females, mean age of 55 years (range, 35 to
Indium labeling of natural or recombinant human b2m 77 years), and a mean time on HD of 11 years (range,
was performed as described previously [10]. Briefly, the 1 month to 27 years). Underlying diseases included glo-
chelator DTPA was covalently bound to (rh)b2m using merulonephritis (N 5 11), hypertensive nephrosclerosis
the bicyclic DTPA anhydride (Aldrich, Deisenhofen, (N 5 3), interstitial nephropathy (N 5 2), nephron-
Germany). The conjugate was separated from free DTPA ophthisis (N 5 2), autosomal-dominant polycystic kidney
by ultrafiltration and stored at 2808C. On the day of disease (ADPKD) (N 5 2), tumor nephrectomy (N 5 2),
injection, approximately 300 mg of DTPA-b2m dissolved and arachidonic acid (AA) amyloidosis (N 5 1). Patients
in citrate buffer were added to 370 to 400 MBq of 111In- had exclusively been on chronic HD using bicarbonate-
buffered dialysate. Until about 1990, regenerated cellu-chloride (Mallinckrodt, Hennef, Germany). The mixture
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losic membranes had been used for most treatments, amyloidosis (mean age of these patients 58 years, range
whereas since that time, the majority of patients had been 43 to 73 years; mean time on HD 15 years, range 10 to
treated with high-flux synthetic dialysis membranes. No 21 years). In this subgroup of patients, significant tracer
patient had been transplanted for more than three months accumulation was noted in the areas of shoulders, carpal
after reaching end-stage renal failure. No patient suf- bones, hips, knees, feet, spine, and elbows (Fig. 1 B, D,
fered from acute infections at the time of scintigraphy. and Table 1). In addition, local tracer accumulation was
Clinical signs and symptoms as well as radiological evi- observed in the area of sternoclavicular joints, bursae
dence of Ab2m amyloidosis were assessed as described adjacent to shoulder and hip joints, and small finger
before [7]. joints (Fig. 1D). All sites with clinical and/or radiological
evidence of Ab2m amyloid deposition revealed local ac-
cumulation of 111In-b2m. In four patients, we were ableRESULTS
to demonstrate local tracer accumulations at sites of his-
Technical aspects tologically proven Ab2m amyloid deposition. No false-
Injection of 111In-labeled natural b2m (patients 1 through negative cases were observed. In three patients who had
17) as well as 111In-labeled rhb2m (patients 18 through undergone scintigraphy with 131I-b2m four to nine years
23) was tolerated well by all patients, and no adverse earlier, qualitatively similar or markedly improved im-
reactions were noted. ages were obtained with 111In-b2m (Fig. 1 and Table 2). In
A significant reduction of the radiation exposure with particular, the more widespread demonstration of local
111In compared with the previous scan employing 131I- tracer accumulation in the hand regions was unlikely to
labeled natural b2m [7] was obtained. Using 111In-labeled be completely attributable to disease progression, as the
b2m, the effective whole-body equivalent radiation dose 131I-b2m scan at best had yielded blurred images (Fig. 1).
measured by dosimetry (performed by repeated whole In the other eight patients, neither clinical nor radio-
body scintigraphy at 1-, 4-, 24-, 48-, 72-, and 144-hours logical evidence of Ab2m amyloidosis was present (meanpostinjection, and concomitant collection of blood sam- age of these patients 50 years, range 35 to 71 years; mean
ples) in a completely anuric patient was calculated as 5.3 time on HD 6 years, range 1 month to 17 years). During
mSv with 37 MBq of injected 111In-b2m. In contrast, with 111In-b2m scintigraphy in this subgroup, minor tracer up-the 131I-b2m scintigraphy, a whole-body equivalent radia- take of the knees was noted in two out of eight patients
tion dose of 11 to 15 mSv had been determined [7]. (Table 1), and very weak tracer uptake also occurred in
The replacement of 131I with 111In allowed the usage
the lower thoracic/lumbar spine in two out of eight pa-of medium energy collimators with higher resolution and
tients (data not shown). In two out of eight patients withhigher sensitivity. As shown in Figure 1, this resulted in
a residual urine production of about 500 mL/day, tracera marked enhancement of the resulting images (Fig. 1).
accumulation in the region of the kidneys reflecting renalFollowing the injection of 111In-b2m, unequivocal local excretion of 111In-b2m and/or free 111In was observed. Notracer accumulations were first noted after 24 hours, and
tracer uptake other than the nonspecific accumulationa scan image of high quality was obtained after 48 hours.
in liver, spleen, and large intestine (discussed previouslyIn contrast, using 131I-b2m, imaging at 24 hours showed
in this article) was observed in a patient (J.G.) withmostly blood-pool effects, and optimal demonstration of
visceral and renal AA amyloidosis on the basis of long-localized tracer deposition required a 72-hour period
standing rheumatoid arthritis who had been on dialysisbetween injection and scan.
for three years.In all patients of both subgroups (natural and recombi-
Scintigraphy with 111In-labeled recombinant human b2m.nant 111In-b2m), local tracer accumulation was noted reg-
As shown in Table 1, four of six patients presented withularly in the liver, to a lesser extent in the spleen, and
clinical and/or radiological signs of Ab2m amyloidosisoccasionally in the large intestine (Figs. 2 and 3). In
(mean age of these patients 54 years, range 50 to 59addition, some nonspecific uptake was observed in mar-
years; mean time on HD 17 years, range 11 to 27 years).row, nasopharyngeal regions, and genital areas. In some
As in the patients with positive natural 111In-b2m scintig-instances, where no strong specific uptake in amyloid
raphy, 111In-rhb2m tracer uptake was significant in alldeposits was present, an apparently more pronounced
these patients, predominantly in shoulders, knees, hips,cardiac and blood pool activity (Figure 3) was observed.
ankles, wrists, and elbows (Fig. 2). In one patient (N.D.;Most likely this is due to technical reasons. Since a prede-
Fig. 2), abnormal posterior thoracic activity was present,termined total number of counts is accumulated per scan
which probably relates to Ab2m amyloid in subscapularimage, more background signal will be collected to
bursae, possibly also to subcutaneous amyloid deposition.achieve the same number of total counts.
In the other two patients, neither clinical nor radiologi-
Scintigraphic findings in hemodialysis patients cal evidence of Ab2m amyloidosis was present (age of
these patients 56 and 77 years, time on HD two and oneScintigraphy with 111In-labeled natural b2m. Nine of 17
patients showed clinical and/or radiological signs of Ab2m months). Very weak tracer uptake was seen in the knee,
Scha¨ffer et al: Scanning for b2m amyloidosis876
Fig. 1. 131Iodine-b2-microglobulin (b2m) scan (performed in 1988, imaging at 72 hours post-tracer injection; A and C) and 111Indium-b2m scintigraphy
(performed in 1993, imaging at 48 hours post-tracer injection; B and D) of the pelvis (anterior image; A and B) and the hand/wrist region (palmar
image; C and D; panel D includes forearm/elbow region) in a 58-year-old patient (H.D.) with severe Ab2m after 16 years of HD (arthralgias,
juxta-articular cystic bone lesions in shoulders, wrists, hips, knees; carpal tunnel surgery; histology obtained at surgery for Baker cyst right knee
positive for Ab2m amyloid). While the 131I-b2m scan allowed the detection of amyloid deposits in the hip region (A), its resolution in the wrist
region (C) was limited [some tracer accumulation can be noted in the region of the right wrist (arrow) but no accumulation is detectable in the
hands facing upward]. In both regions, resolution is markedly improved with the 111In-b2m scan (B and D).
ankle, shoulder, and/or wrist regions, and no other sig- One patient (S.K.) was examined using both the scin-
tigraphy with 111In-labeled natural b2m (in 1993) andnificant tracer accumulation was observed. As an exam-
ple for the negative controls, the image of patient F.Sp. recombinant human b2m (in 1998). During this period,
considerable progress of local tracer accumulations oc-who had become anephric by tumor nephrectomy one
month earlier is shown in Figure 3. curred (Table 1).
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Fig. 2. 111In-labeled recombinant human b2m whole-body scintigraphy
(left, anterior whole-body image; right, posterior whole-body image;
Fig. 3. Negative 111In-labeled recombinant b2m scan (left, anteriorimaging performed 72 hours postinjection) in a 50-year-old patient
whole-body image; right, posterior whole-body image; imaging per-(N.D.) with severe Ab2m after 27 years of HD (arthralgia predominantly
formed 72 hours postinjection) in a 77-year-old patient (F.Sp.) onein the shoulders; bilateral carpal tunnel surgery; wrist cystic bone lesions
month after tumor nephrectomy of the second kidney. The first kidneywith histologically proven Ab2m).
had been lost several years earlier. Weak tracer accumulation is present
in both knee and ankle regions.
With regard to specificity of the scan, both with natural
and recombinant 111In-labeled b2m scintigraphy, all areas demonstrated in our previous studies by the good corre-of clinical, radiological, or histologic evidence of Ab2m lation of clinical/radiological and scan findings, by theamyloid exhibited tracer accumulation. The sensitivity
demonstration of tracer enrichment in amyloid tissueof the 111In-b2m scan markedly exceeded that of the clini- and isolated Ab2m amyloid fibers, by the absence ofcal and radiological assessment, as indicated by the high
tracer accumulation in short-term HD patients with non-image resolution (Fig. 1 B, D) and by the fact that more
amyloid inflammatory disease, and by the fact that nothan 50% of the sites with specific tracer accumulation
uptake of radiolabeled nanocolloidal albumin (a nonspe-failed to show clinical or radiological evidence of amyloid
cific marker of inflammation taken up by macrophages)deposition.
was noted in areas of Ab2m deposition [7]. These data
do not support the notion presented by Gejyo et al that
DISCUSSION the dominant mechanism of radiopharmaceutical uptake
into Ab2m amyloid deposits is a significant tracer uptakeNoninvasive imaging by 131I-b2m scintigraphy of Ab2m
by surrounding macrophages [14]. Sensitivity of the 131I-amyloidosis has been introduced previously in end-stage
b2m scintigraphy markedly exceeded a combined clinicalrenal disease patients [6, 7]. This method has been suc-
and radiological approach [7]. Despite evoking wide in-cessfully reproduced in Japan using b2m derived from
terest, however, the clinical use of 131I-b2m scintigraphyhuman uremic plasma ultrafiltrate [11] or urine [12], as
has been hampered by the relatively high dose of radia-well as in Spain using b2m derived from human urine
[13]. Specificity of the 131I-b2m scintigraphy had been tion exposure for the patients.
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Table 1. List of patients studied by 111In-b2m or 111In-rhb2m scintigraphy
Age Time on HD Shoulder Wrist Hip Knee Ankle
Clinical/x-ray Scan
Patient Ab2m status year/month R L R L R L R L R L Sumyears
Scintigraphy with 111In-labeled natural b2m
H.D. 58 16 pos 93/05 3 3 3 3 3 3 3 2 2 2 27
F.R. 59 20 pos 93/07 3 3 3 3 3 3 3 3 1 1 26
E.W. 64 14 pos 93/08 3 2 1 0 2 1 2 1 0 0 12
T.P. 63 10 pos 93/08 2 2 2 2 1 1 0 0 0 0 10
B.S. 43 21 pos 93/08 2 2 2 1 2 2 1 1 0 0 13
H.R. 54 20 pos 93/10 2 2 2 2 2 2 2 2 0 0 16
H.B. 55 11 pos 93/11 1 1 0 0 1 0 0 0 0 0 3
H.K. 73 15 pos 93/11 2 1 1 1 2 1 3 1 0 0 12
S.K. 52 10 pos 93/12 2 0 0 0 1 1 0 0 0 0 4
E.T. 49 17 neg 93/06 0 0 0 0 0 0 0 0 0 0 0
S.S. 37 13 neg 93/06 0 0 0 0 0 0 1 1 0 0 2
K.B. 35 1 neg 93/07 0 0 0 0 0 0 0 0 0 0 0
F.S. 71 4 neg 93/08 0 0 0 0 0 0 0 1 0 0 1
A.C. 42 4 neg 93/08 0 0 0 0 0 0 0 0 0 0 0
C.N. 62 0 neg 93/08 0 0 0 0 0 0 0 0 0 0 0
J.G. 52 3 neg 93/10 0 0 0 0 0 0 0 0 0 0 0
W.Ho. 52 4 neg 93/12 0 0 0 0 0 0 0 0 0 0 0
Scintigraphy with 111In-labeled recombinant human b2m
S.K. 57 14 pos 98/04 2 2 2 2 2 2 2 2 2 2 20
R.P. 59 15 pos 98/04 2 2 1 2 2 2 2 2 2 2 19
N.D. 50 27 pos 98/07 3 3 2 2 2 2 3 3 2 2 24
W.H. 50 11 pos 98/07 3 3 1 1 2 2 2 2 1 1 18
R.R. 56 0 neg 98/04 1 1 1 0 0 0 1 1 1 1 7
F.Sp. 77 0 neg 98/05 0 0 0 0 0 0 1 1 1 1 4
Clinical/radiological Ab2m status (positive/negative) and results of scintigraphy for the main joint regions are indicated (strong accumulation was also noted in
the elbow regions of patients H.D., N.D., and W.H., but could not be evaluated systematically, since the elbows often localized at the edge or outside of the imaging
area). Note that patient S.K. underwent both 111In-b2m and 111In-rhb2m scintigraphy. Tracer accumulations over specific regions were graded from 0 to 3 as described
in the Methods section.
Table 2. Comparison of scintigraphic findings in three Ab2m-positive patients studied both by 131I-b2m and by 111In-(rh)b2m scintigraphy
Age Time on HD Shoulder Wrist Hip Knee
Clinical/x-ray Time of scan Type of
Patient Ab2m status year/month tracer R L R L R L R L Sumyears
H.D. 53 11 pos 88/11 131I-b2m 3 3 0 1 2 3 2 2 16
58 16 pos 93/05 111In-b2m 3 3 3 3 3 3 3 2 23
F.R. 54 16 pos 88/11 131I-b2m 3 2 2 2 2 2 2 2 17
59 20 pos 93/07 111In-b2m 3 3 3 3 3 3 3 3 24
N.D. 41 17 pos 88/11 131I-b2m 2 3 0 0 1 2 2 2 12
50 27 pos 98/07 111In-rhb2m 3 3 2 2 2 2 3 3 20
In comparison to 131I, the 111In isotope offers several dure becomes more convenient than the previously em-
ployed method of labeling b2m with 131I for eachadvantages, including a shorter tracer half-life and better
radiation characteristics. Scintigraphy with 111In-labeled application [6, 7].
With the new indium labeling, both the image resolu-cells, such as leukocytes, or molecules, such as antibod-
ies, has therefore become standard clinical practice tion and the radiation exposure could be markedly im-
proved compared with the previous iodine-labeling[15–17]. In contrast to iodine, which can be bound di-
rectly to tyrosine residues in protein [8], radiolabeling method. In particular, in the case of small joints, such
as in the hand, the previous 131I-b2m scintigraphy yieldedof a protein with indium requires the technically more
difficult prior conjugation of the protein with a chelator only blurred images because of limited resolution and
statistics. Using 111In-b2m, tracer accumulation in a singlemolecule, such as DTPA [15]. On the other hand, how-
ever, the DTPA-protein conjugation can be performed finger joint could be discriminated, which is similar to
the findings reported by Nelson et al using 123I-serumwell in advance (under our study conditions, DTPA-
conjugated b2m was stable in frozen condition over a amyloid P-component (SAP) scintigraphy in HD pa-
tients [18]. In contrast to the 123I-SAP scintigraphy, how-period of at least three months). Immediately prior to
tracer injection for scintigraphy, DTPA-b2m can be eas- ever, the good sensitivity in the areas of large joints,
such as the hips, that we had observed with 131I-b2, wasily labeled with 111In. Consequently, the labeling proce-
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maintained with 111In-b2m. Radiation exposure during In particular, in the knee region, similar findings have
been obtained with natural 111In-labeled b2m (Table 1)the 111In-b2m scintigraphy was now reduced to approxi-
mately 5.3 mSv (from 11 to 15 mSv with 131I-b2m), which or natural 131I-labeled b2m (J. Floege, unpublished obser-
vation). These latter findings suggest that such faintis comparable to that of a conventional bone scintigraphy
[19] or the 123I-SAP scan (4.5 mSv) [20]. tracer enrichment is a nonspecific phenomenon that may,
for example, originate from capture of the radioligandSpecificity of the b2m scintigraphy was apparently not
affected by changing the radioligand. This is indicated within the joint fluid. Alternatively, we cannot fully ex-
clude that such faint tracer accumulations represent sub-first by the similarity of images obtained with 131I-b2m and
111In-b2m in the few patients who were investigated se- clinical Ab2m amyloid deposits. However, this later pos-
sibility appears highly unlikely given the findings inquentially with both methods, secondly by the correla-
tion with clinical/radiological as well as histologic evidence patient F.Sp., who was scanned one month after the
onset of acute uremia (Fig. 3).for Ab2m, and thirdly by a negative scan in a patient
with AA amyloidosis caused by rheumatoid arthritis. Con- In conclusion, the change of the b2m-labeling method
from 131I to DTPA conjugation with subsequent chelationsistently negative scans were obtained over the joint re-
gions of very short-term HD patients. Although we had no of 111In led to a significant reduction of the radiation
exposure and a markedly improved image quality of theopportunity to systematically correlate the scintigraphic
findings with histologic data, it is notable that the sterno- b2m scintigraphy, which now allows for the imaging of
small joints and thereby enhances the sensitivity of theclavicular joints, which frequently have been shown to
contain Ab2m [21], were rarely visualized by scintigra- diagnostic method. In addition, the availability of ho-
mogenous recombinant human b2m provides a safe andphy. This observation likely relates to the small size of
the joints, and in particular to the blood-pool effect of stable protein source. Given the similarity of the findings
obtained with the three scan methods, that is, 131I-b2m,the superimposed large vessels in the upper thoracic
region. Similarly, the specific detection of vertebral amy- 111In-b2m, and 111In-rhb2m scintigraphy, we infer that the
scan specificity as extensively described previously [7]loid deposits may be limited by the concomitant tracer
content of the blood pool and, possibly, active marrow. was maintained. Thus, 111In-b2m scintigraphy has achieved
the potential to serve as a more widely applicable tech-Tracer accumulation in the liver and, to a lesser extent,
in the spleen of most patients cannot be used as evidence nique for early, specific, and noninvasive diagnosis of
Ab2m amyloidosis in end-stage renal failure patients. Infor Ab2m deposition, since it is observed with many other
111In-labeled tracers as well [22–26]. Rather, this finding particular, this technique may aid to define the epidemi-
ology of the amyloidosis better, and to identify bothappears to be related to uptake of either 111In alone or the
111In-labeled proteins by the reticuloendothelial system. patient- and dialysis-related risk factors as well as poten-
tial preventive measures.Thus, a visualization of specific visceral amyloid deposits
is not feasible; however, the target of b2m scintigraphy
is the osteoarticular system, and pathological studies ACKNOWLEDGMENTS
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